PolyPeptide Group AG - Half-year report 2021

Leading CDMO for complex peptide manufacturing

Innovation – Excellence – Trust

Financial Highlights

135.1

Revenue in EUR million

+54% vs H1 2020

43.2

32.0%

margin

Adjusted EBITDA in EUR million

+133% vs H1 2020

24.6

18.2%

margin

Result for the period in EUR million

+214% vs H1 2020

It is with pleasure and satisfaction that we present the first half-year report of PolyPeptide Group AG following the successful IPO and listing on SIX Swiss Exchange at the end of April 2021. In a business environment still very much impacted by the global coronavirus pandemic, the whole Group continued to strive for flawless execution and for the delivery of high-quality services to our customers.

Quick access

Overview

The overview section includes the editorial of the Chairman of the Board of Directors and the CEO, the key figures for the reporting period as well as a few charts to illustrate the profile of PolyPeptide.

Business review

In the business review section, we discuss the performance for the reporting period and our strategic progress. It also includes a paragraph on the outlook and our mid-term guidance.

Financial report

The financial report includes our consolidated financial statements as well as the notes that we prepare in accordance with IFRS.

Download-Center

Financial Highlights

Editorial

Quick access

Downloads